Chemical and biological aspects of posaconazole as a classic antifungal agent with non-classical properties: highlighting a tetrahydrofuran-based drug toward generation of new drugs
Abstract Posaconazole (PSZ, SCH 56592), is a new generation of orally active triazole antifungal agent with a tetrahydrofuran center, derived from itraconazole (ITZ). This drug has a broader spectrum of activity respect to the dioxolane-based triazoles. Structurally, PSZ molecule with four chiral centers and long side chain has a complicated structure. In this review, we describe general aspects of PSZ, including chemistry, pharmacological properties, mechanism of action, synthetic strategies, synthesis of key intermediates, structure-antifungal activity relationships, and the design of its prodrugs. Finally, the non-classical properties of PSZ including antitrypanosomal, antileishmanial and hedgehog (Hh) signaling pathway inhibitory activities will be discussed. By highlighting the information and experiences gained with PSZ, we can better move toward newer compounds of this generation. Graphical abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Medicinal chemistry research - 31(2022), 6 vom: 19. Mai, Seite 833-850 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dadashpour, Sakineh [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 |
|---|
| doi: |
10.1007/s00044-022-02901-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR047165936 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR047165936 | ||
| 003 | DE-627 | ||
| 005 | 20230519221816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220603s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00044-022-02901-2 |2 doi | |
| 035 | |a (DE-627)SPR047165936 | ||
| 035 | |a (SPR)s00044-022-02901-2-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dadashpour, Sakineh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Chemical and biological aspects of posaconazole as a classic antifungal agent with non-classical properties: highlighting a tetrahydrofuran-based drug toward generation of new drugs |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
| 520 | |a Abstract Posaconazole (PSZ, SCH 56592), is a new generation of orally active triazole antifungal agent with a tetrahydrofuran center, derived from itraconazole (ITZ). This drug has a broader spectrum of activity respect to the dioxolane-based triazoles. Structurally, PSZ molecule with four chiral centers and long side chain has a complicated structure. In this review, we describe general aspects of PSZ, including chemistry, pharmacological properties, mechanism of action, synthetic strategies, synthesis of key intermediates, structure-antifungal activity relationships, and the design of its prodrugs. Finally, the non-classical properties of PSZ including antitrypanosomal, antileishmanial and hedgehog (Hh) signaling pathway inhibitory activities will be discussed. By highlighting the information and experiences gained with PSZ, we can better move toward newer compounds of this generation. Graphical abstract | ||
| 650 | 4 | |a Posaconazole |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antifungal activity |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Triazoles |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Synthesis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SAR study |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ghobadi, Elham |4 aut | |
| 700 | 1 | |a Emami, Saeed |0 (orcid)0000-0003-1665-6621 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicinal chemistry research |d Cambridge, Mass. [u.a.] : Birkhäuser Boston, 1991 |g 31(2022), 6 vom: 19. Mai, Seite 833-850 |w (DE-627)SPR000381640 |w (DE-600)2191978-1 |x 1554-8120 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2022 |g number:6 |g day:19 |g month:05 |g pages:833-850 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00044-022-02901-2 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2022 |e 6 |b 19 |c 05 |h 833-850 | ||